A Phase 3 study investigating talquetamab in combination therapies for relapsed or refractory multiple myeloma reached its primary completion milestone on 2026-04-01. The trial, identified as NCT06208150, enrolled 795 participants to evaluate different treatment regimens.
Background
This study focuses on talquetamab, an investigational therapy for multiple myeloma. The trial specifically targets participants with relapsed or refractory myeloma who have previously received an anti-CD38 antibody and lenalidomide, indicating a patient population with limited treatment options.
Trial design
The Phase 3 study (NCT06208150) is designed to compare different treatment combinations for relapsed or refractory multiple myeloma. It has an estimated enrollment of 795 participants. The trial evaluates regimens including talquetamab plus pomalidomide and talquetamab plus teclistamab against control arms of elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd). The specific primary outcomes for this study were not detailed in the source information.
What this means
The primary completion of this Phase 3 study signifies that data collection for the trial's main objectives has concluded. While this milestone does not yet include the release of specific efficacy or safety results, it indicates progress towards understanding the potential benefits of talquetamab in combination with other agents for patients with relapsed or refractory multiple myeloma. Clinicians and researchers will anticipate the future publication of these results to assess the impact of these treatment regimens on patient outcomes in this challenging disease setting.
Source
Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT06208150, titled "A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide", was updated on 2026-04-01 on clinicaltrials.gov.